CAR-T cell therapy for refractory/relapsed hematological malignancies in central nervous system

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025432

Enrollment

Unknown

Registered

2019-08-26

Start date

2019-08-25

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed/refractory hematological malignancies in central nervous system

Interventions

CAR-T group:CAR-T cell treatment

Eligibility

Sex/Gender

All

Age

No minimum to 70 Years

Inclusion criteria

Inclusion criteria: 1. Refractory/relapsed hematological malignancies in central nervous system; 2. CD19 or BCMA positive; 3. ECOG 0-2.

Exclusion criteria

Exclusion criteria: 1. Active infection; 2. HIV infection; 3. Abnormal organ dysfunction.

Design outcomes

Primary

Measure	Time frame
complete remission rate;the rate of central nervous system complication;cytokine release syndrome;infection;pancytopenia;	—

Countries

China

Contacts

Public ContactHe Huang

The First Affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026